预处理GFR斜率预测Dapagliflozin响应在IgA脏病中
Hiroyuki Ueda1, Nobuo Tsuboi1, Kei Matsumoto1
1Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Kidney international reports
|July 18, 2025
概括
达帕格利弗洛辛减缓了IgA脏病 (IgAN) 患者估计的淋巴细胞过率 (eGFR) 的下降. 治疗前更快的eGFR斜率表明,达帕格利弗洛辛治疗后的改善更大.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 达帕格利弗洛辛在IgA脏病 (IgAN) 中显示出脏保护作用.
- 在标准护理下缓慢进展的IgAN中,基线估计的淋巴细胞过率 (eGFR) 斜率和治疗结果之间的关系需要澄清.
研究的目的:
- 调查接受达帕格利弗洛辛的Igan患者治疗前的eGFR斜率和治疗后的结果之间的关联.
- 为了确定基线eGFR斜率是否可以预测Igan中的治疗反应.
主要方法:
- 84名活检确认的Igan患者的回顾性分析,这些患者接受了达帕格利弗洛辛治疗.
- 在治疗前和治疗后的纵向eGFR斜率和尿蛋白与肌素比率 (UPCR) 的比较.
- 多变量回归以评估前处理eGFR斜率和后处理eGFR变化之间的关联.
主要成果:
- 达帕格利弗洛辛治疗显著改善了eGFR的斜率,从-1.92到-0.69毫升/分钟/1.73米2/年.
- 时间平均UPCR在治疗后保持稳定.
- 治疗前更剧烈的EGFR下降与治疗后更大的EGFR改善有关.
- 预处理eGFR斜率独立预测后处理eGFR斜率.
结论:
- 达帕格利弗洛辛在IGAN患者中减缓了eGFR的下降.
- 治疗前的eGFR斜率是达帕格利弗洛辛在IgAN中的有效性的重要预测指标.
- 预处理eGFR斜率可能有助于个性化针对IGAN的达帕格利弗洛辛治疗.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
262
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
262
01:11Renal Failure: Dose Adjustments
161
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
161
01:28Glomerular Filtration Rate and its Regulation
3.4K
The Glomerular Filtration Rate (GFR) is a measure of kidney function, reflecting the volume of filtrate formed per minute in the kidneys. On average, GFR is approximately 125 mL/min in males and 105 mL/min in females. Maintaining a relatively constant GFR is essential for the kidneys to effectively regulate body fluid homeostasis and maintain extracellular stability.
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
3.4K
01:17Factors Affecting Renal Clearance: Renal Impairment
162
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
162
01:24Glucagon-like Receptor Agonists
421
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
421
01:22Renal Drug Excretion: Effect of Urine pH, Flow Rate, and Drug pKa
277
The pH of urine, the drug's pKa, and the urine flow rate are vital parameters for drug reabsorption and excretion. Urinary pH varies between 4.6 and 8.0 and is influenced by diet, drug intake, and the patient's pathophysiology. It affects a drug's ionization state and reabsorption. For instance, carbohydrate-rich food produces alkaline urine promoting drug excretion, while proteins and certain medications like ascorbic acid lead to acidic urine enhancing reabsorption.
The pKa of a...
The pKa of a...
277